| Achieved approximately 250% revenue growth in 2025, following a successful year of quantitative and qualitative expansion.
| Secured over 100 new clients, including Samjin Pharm and Handok, and more than 20 global projects.
| Aims for "Global Expansion" and "Advanced Drug & Medical Device Development" as key goals for 2026.
February 26, 2026 – JNPMEDI, an AI platform-based consulting firm specializing in drug and innovative medical device development, announced its commitment to solidifying its position as a global partner for new drug and medical device development in 2026, building on its remarkable achievements in 2025.
Following a 500% growth rate in 2024, JNPMEDI continued its momentum in 2025 with a 250% increase in revenue, successfully achieving both quantitative growth and qualitative enhancement. Last year alone, the company attracted more than 100 new clients, including pharmaceutical and digital health companies such as Samjin Pharm, Handok, DDH, Redicure, and Mediiot. Additionally, it secured over 20 global clinical trial projects. This growth signifies market-wide recognition of JNPMEDI’s expertise in clinical operations, data management, and global regulatory compliance.
Throughout 2025, JNPMEDI focused on strengthening its integrated solutions that cover the entire clinical trial lifecycle—from design and operation to data collection, management, and regulatory response. The company’s solutions have maximized utility by structurally reducing administrative burdens and data management inefficiencies while incorporating data standards and submission requirements from major regulatory bodies such as the US FDA, EMA, and MFDS.
A standout success case is the clinical trial approval of EverEx’s digital therapeutic (DTx) "Mora Cure." By managing the clinical operations and data, JNPMEDI helped EverEx obtain the first-ever domestic marketing authorization for a musculoskeletal digital therapeutic. This achievement demonstrates that JNPMEDI’s solutions are not merely supportive tools but essential drivers in achieving the final goal of regulatory approval, even in emerging fields with new regulatory frameworks.
Leveraging these capabilities, JNPMEDI continues to build success stories in traditional drug development through collaborations with numerous pharmaceutical companies. Using its AI-based platform, the company proposes "cost-efficient clinical" models that significantly reduce time and costs compared to traditional methods, accelerating the commercialization of its clients' new drugs.
For 2026, JNPMEDI has identified "Global Expansion" and "Advancement in Drug and Medical Device Development" as its core objectives. The company plans to leverage its accumulated experience and infrastructure to aggressively enter the global market.
To support this expansion, JNPMEDI has been actively recruiting top-tier talent. Late last year, the company appointed Kim Yu-mi, a former Deputy Minister of the Ministry of Food and Drug Safety (MFDS) and a global regulatory expert, as an advisor. It also brought on Vice President Na Hyun-hee, a clinical development strategy expert with over 20 years of experience in the pharmaceutical and CRO industries. JNPMEDI plans to establish its position as an integrated clinical operations partner that meets global standards by expanding strategic collaborations with global biotech firms and enhancing its multi-national clinical trial capabilities. Plans are also underway to establish a hub in the Asia-Pacific (APAC) region and formally enter the U.S. market this year.
"2025 was a significant year where we proved the core competitiveness of our solutions alongside our outward growth," said JNPMEDI CEO Jerry Jung. "In 2026, we will serve as a key partner for domestic and international companies preparing for drug and medical device development, building a foundation for global growth together."
| Achieved approximately 250% revenue growth in 2025, following a successful year of quantitative and qualitative expansion.
| Secured over 100 new clients, including Samjin Pharm and Handok, and more than 20 global projects.
| Aims for "Global Expansion" and "Advanced Drug & Medical Device Development" as key goals for 2026.
February 26, 2026 – JNPMEDI, an AI platform-based consulting firm specializing in drug and innovative medical device development, announced its commitment to solidifying its position as a global partner for new drug and medical device development in 2026, building on its remarkable achievements in 2025.
Following a 500% growth rate in 2024, JNPMEDI continued its momentum in 2025 with a 250% increase in revenue, successfully achieving both quantitative growth and qualitative enhancement. Last year alone, the company attracted more than 100 new clients, including pharmaceutical and digital health companies such as Samjin Pharm, Handok, DDH, Redicure, and Mediiot. Additionally, it secured over 20 global clinical trial projects. This growth signifies market-wide recognition of JNPMEDI’s expertise in clinical operations, data management, and global regulatory compliance.
Throughout 2025, JNPMEDI focused on strengthening its integrated solutions that cover the entire clinical trial lifecycle—from design and operation to data collection, management, and regulatory response. The company’s solutions have maximized utility by structurally reducing administrative burdens and data management inefficiencies while incorporating data standards and submission requirements from major regulatory bodies such as the US FDA, EMA, and MFDS.
A standout success case is the clinical trial approval of EverEx’s digital therapeutic (DTx) "Mora Cure." By managing the clinical operations and data, JNPMEDI helped EverEx obtain the first-ever domestic marketing authorization for a musculoskeletal digital therapeutic. This achievement demonstrates that JNPMEDI’s solutions are not merely supportive tools but essential drivers in achieving the final goal of regulatory approval, even in emerging fields with new regulatory frameworks.
Leveraging these capabilities, JNPMEDI continues to build success stories in traditional drug development through collaborations with numerous pharmaceutical companies. Using its AI-based platform, the company proposes "cost-efficient clinical" models that significantly reduce time and costs compared to traditional methods, accelerating the commercialization of its clients' new drugs.
For 2026, JNPMEDI has identified "Global Expansion" and "Advancement in Drug and Medical Device Development" as its core objectives. The company plans to leverage its accumulated experience and infrastructure to aggressively enter the global market.
To support this expansion, JNPMEDI has been actively recruiting top-tier talent. Late last year, the company appointed Kim Yu-mi, a former Deputy Minister of the Ministry of Food and Drug Safety (MFDS) and a global regulatory expert, as an advisor. It also brought on Vice President Na Hyun-hee, a clinical development strategy expert with over 20 years of experience in the pharmaceutical and CRO industries. JNPMEDI plans to establish its position as an integrated clinical operations partner that meets global standards by expanding strategic collaborations with global biotech firms and enhancing its multi-national clinical trial capabilities. Plans are also underway to establish a hub in the Asia-Pacific (APAC) region and formally enter the U.S. market this year.
"2025 was a significant year where we proved the core competitiveness of our solutions alongside our outward growth," said JNPMEDI CEO Jerry Jung. "In 2026, we will serve as a key partner for domestic and international companies preparing for drug and medical device development, building a foundation for global growth together."